Serina Therapeutics (SER) Price to Sales (2018 - 2025)

Serina Therapeutics has disclosed Price to Sales across 8 years of filings, most recently posting 480.72 for Q2 2025.

• In Q2 2025, Price to Sales fell 70.89% year-over-year to 480.72; the TTM figure through Jun 2026 stood at 244.51 (down 49.14% YoY), while the FY2025 annual figure was 158.19, down 75.97% from the prior year.
• Price to Sales came in at 480.72 for Q2 2025 at Serina Therapeutics, up from 2633.47 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 231452.69 in Q1 2022 to a low of 2633.47 in Q4 2024.
• Average Price to Sales over 5 years is 54346.35, with a median of 35491.11 recorded in 2021.
• Year-over-year, Price to Sales jumped 490.52% in 2022 and sank 54895.01% in 2024.
• Over 5 years, Price to Sales stood at 53067.42 in 2021, then surged by 76.19% to 93497.33 in 2022, then slumped by 99.99% to 4.81 in 2023, then sank by 54895.01% to 2633.47 in 2024, then jumped by 118.25% to 480.72 in 2025.
• Per Business Quant data, the three most recent Price to Sales figures were 480.72 in Q2 2025, 2633.47 in Q4 2024, and 4249.11 in Q3 2024.